ANKE BIO: Innovative drug HuA21 injection will announce clinical research data at the 2025 European Society for Medical Oncology (ESMO) annual meeting
ANKE BIO announced that it will present the clinical research data of its innovative drug HuA21 at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The study of the drug in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric cancer has shown good anti-tumor activity and safety, supporting the Phase III clinical trial and enhancing the product's market competitiveness
According to the Zhitong Finance APP, ANKE BIO (300009.SZ) announced that from October 17 to 21, 2025, it will present the latest research results of its self-developed biopharmaceutical recombinant anti-HER2 humanized HuA21 monoclonal antibody injection (hereinafter referred to as "HuA21") in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma in a dose-escalation and expansion study at the European Society for Medical Oncology (ESMO) annual meeting held in Berlin, Germany.
The clinical research data disclosed at the ESMO annual meeting further confirms the good anti-tumor activity and tolerable safety of HuA21 in combination with trastuzumab and chemotherapy for the treatment of HER2-positive advanced gastric/gastroesophageal junction adenocarcinoma, providing support for the Phase III clinical trial and accelerating the drug development process. In addition, the positive clinical data will provide strong support for the product's market prospects, helping to enhance the future market competitiveness of the company's products
